Objective. Examination of prevalence, intensity and associations of pain in persons with multiple sclerosis (MS).
Subjects. Six hundred and fifty consecutive MS patients diagnosed according to the Revised McDonald criteria (2005) , from the aforementioned centers, over the period of 6 months.
Methods. A semistructured questionnaire was administered during a face-to-face interview with neurologists who also performed Expanded Disability Status Scale (EDSS), the Hamilton Rating Scale for Depression (HDRS) and Hamilton Rating Scale for Anxiety (HARS). To recognize predictive factors for the presence of pain, the linear regression analysis was used.
Results. Lifetime prevalence of pain was 66.5% (point prevalence 5 44.3%). The prevalence of the comorbidity of pain and depression was 29.1%. Older age (P < 0.001), primary-progressive MS (P 5 0.034), higher EDSS score (P 5 0.008), higher scores of HDRS (P < 0.001), and HARS (P < 0.001) were significantly associated with pain. Finally, in our multivariate linear regression analysis, anxiety (P < 0.001) was the independent predictor of pain.
Introduction
Multiple sclerosis (MS) is an inflammatory and neurodegenerative chronic disease of the central nervous system (CNS). Pain is a common symptom in MS, which has been recently estimated to be experienced by 63% of patients [1] . Published pain prevalence in MS range widely because of significant differences in patients' samples and study design [1] [2] [3] . Additionally, therefore the risk factors reported to be associated with greater likelihood of pain in adults with MS also differ in various studies [4] . Italian multicenter cross-sectional study as one of the largest epidemiological surveys, which included 1,672 MS patients, demonstrated that 43% of patients experienced pain and found that age, disease course, diseases duration and disability correlated with the presence of pain [2] .
The WHO classifies pain as nociceptive, neuropathic and psychogenic [5] . Nociceptive pain is pain resulting from nociceptor activation by tissue-damaging stimuli. Neuropathic pain is a consequence of a lesion affecting the somatosensory system. According to classification proposed by O'Connor et al., there are three main types of MS-related pain: neuropathic pain, musculoskeletal, nociceptive pain (i.e., painful tonic spasms, pain secondary to spasticity, pain related to being wheelchair bound), and headaches [4] .
The aim of this multicenter, international cross-sectional survey was to characterize, using a structured questionnaire, the prevalence and clinical characteristics of pain in a cohort of well-defined MS patients. [6] , diagnosed and followed in the above mentioned centers over the period of 6 months. Patients who had a relapse in the last month before the beginning of the study were excluded.
Material and Methods

Study Participants
This survey was approved by Institutional Review Boards in all centers.
Measurements
The questionnaire comprised age, gender, duration and course of the disease, Expanded Disability Status Scale (EDSS) [7] , and type of pain including its therapy. Pain associated with MS was classified as neuropathic pain (continuous central neuropathic pain: neuropathic extremity pain; intermittent central neuropathic pain: Lhermitte's sign, trigeminal neuralgia), musculoskeletal, that is, nociceptive pain (low back pain and painful tonic spasms), and headache (mixed neuropathic and nonneuropathic pain) [4] . We considered pain symptoms at any point during the course of the patients' disease and at the time of evaluation. Pain severity was assessed using 0-100 mm numerical rating scale (Visual analog scale-VAS) [8] . A higher score indicates greater pain intensity.
The severity of depressive symptoms and anxiety were quantified in all patients using the Hamilton Rating Scale for Depression (HDRS) [9] and Hamilton Rating Scale for Anxiety (HARS) [10] . Both HDRS and HARS are clinicianadministered estimation scales that are conducted using a semistructured interview. The suggested cutoff values for HDRS are 0-9 (no depression), 10-13 (mild depression), 14-17 (mild to moderate depression), and >18 (moderate to severe depression) [9] . The total score of the HARS ranges from 0 to 56, in which value <17 indicates no or mild anxiety, values between 18 and 24 mild to moderate anxiety and values between 25 and 30 moderate to severe anxiety [10] .
Statistical Analysis
Descriptive statistics were computed to identify the point and lifetime prevalence of pain in MS patients. Patients' characteristics for the "pain" and "no pain" groups were compared with Chi square and Kruskal-Wallis tests for categorical and Mann-Whitney test for not normally distributed continuous variables. Additionally, we used ANOVA for evaluating differences among normally distributed continuous variables. Spearman's correlation coefficients were used to determine the relationship between the presence of pain and both HDRS and HARS scores. To recognize predictive factors for the presence of pain among study participants, the univariate and multivariate linear regression analyses were performed. The SPSS 17.0 statistical software package (SPSS Inc., Chicago, IL, USA) was used to perform the statistical analysis.
Results
Demographic and clinical data from 650 patients with diagnosis of MS were collected by questionnaires in seven MS centers (Table 1) . Questionnaires were divided into pain (432; 66.5%) and no pain (n 5 218; 33.5%) group. Patients with pain were significantly older, had a higher EDSS score and also higher both HDRS and HARS scores. The pain group comprised marginally significantly (P 5 0.054) higher proportion of persons with SP and PP disease.
According to the values of HDRS (scores > 9) 54.7% had depression (mild-17.9%; mild to moderate-12.9%; moderate to severe-23.9%). Out of 288 persons experiencing any pain at the time of evaluation, 189 (65.6%) met depression criteria (HDRS score > 9). The prevalence of the comorbidity of pain and depression is present in 29.1% of participants. HARS indicated no or mild anxiety in 79.9% patients, mild to moderate in 13.2%, and moderate to severe in 6.9%. There is significant correlation between presence of pain at the time of evaluation and both HDRS (q 5 20.287, P 5 0.001) and HARS (q 5 20.344, P 5 0.001).
Different categories of prevalence in the total cohort of assessed MS patients are presented in Table 2 . Lifetime prevalence of pain in the sample of 650 MS patients was 66.5%, while point prevalence was 44.3%. Additionally, we quantified prevalence of neuropathic extremity pain (52.9%), Lhermitte's sign (19.2%), trigeminal neuralgia (5.7%), low back pain (26.6%), painful tonic spasms (9.5%), and headache (39.5%). According to VAS scale, 35.6% of our 432 patients with pain described their pain intensity as mild, 37.6% as moderate, and 12.4% as severe.
Out of 650 patients, 57.4% were taking pain medication during entire MS course: nonsteroid anti-inflammatory drugs-48.2%, trycyclic antidepressants-10.8%, antiepileptic medications-4.9%, and spasmolytics-9.5%.
Univariate linear regression analyses (dependent variable: presence of pain) showed that older age (P < 0.001), primary-progressive course of MS (P 5 0.034), higher EDSS score (P 5 0.008), higher scores of HDRS (P < 0.001), and HARS (P < 0.001) were the significant predictors of pain in our MS patients (Table 3) . Multivariate linear regression analysis revealed only age (standardized beta coefficient 5 20.178, P < 0.001) and anxiety, measured by HARS (standardized beta coefficient 5 20.198, P 5 0.005) as independent predictors of pain in this study.
Discussion
This study assessed the prevalence of pain in large cohort of well-defined MS patients from several centers 
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in Serbia, Croatia and the Republic of Srpska-Bosnia and Herzegovina. Lifetime prevalence of pain in our sample of 650 MS patients was 66.5%, while point prevalence was 44.3%. This lifetime prevalence is in line with heterogeneous published prevalence of pain at any point during the course of the patients with MS which ranges widely from 34% to 92% [2, 4, [11] [12] [13] . Recently, a systematic review and meta-analysis showed an overall pain prevalence of 63% [1] .
Several types of pain are associated with MS. Criteria used to define the various types of MS-related pain are different. It is essential to adequately define the various types of pain to better understand the underlying pathophysiological mechanisms and to consequently apply the proper treatment strategy. The prevalence of various types of pain varies among numerous studies. However, neuropathic pain and headaches are the most prevalent according to the published data [3] . Our results are in accordance with those findings, as most prevalent types of pain in our survey were also neuropathic extremity pain (52.9%) and headache (39.5%). Low back pain (26.6%) was also very common in our MS patients with prevalence very similar to that reported in above mentioned systematic review [3] . Prevalence of Lhermitte's sign (19.2%), trigeminal neuralgia (5.7%), and painful tonic spasms (9.5%) were also registered in our study. Recently, similarly, Osterberg et al. found trigeminal neuralgia in 4.9% of MS patients [12] , although previous studies detected less frequent occurrence of trigeminal neuralgia in MS patients of 1-2% [2, 14, 15] .
The pain severity in MS has been described in several studies. In most of them, the average pain intensity was estimated as moderate or mild [16, 17] . Similarly, according to VAS scale, in our study majority of patients had mild or moderate pain, and only about 10% reported their pain as severe.
To determine risk factors for pain in MS, several studies have compared MS patients with and without pain [4] . The results of those studies are rather inconsistent but in the majority, the risk factors for development of pain in MS patients were older age, longer disease duration, and higher EDSS, as a measure of disease severity [2, 16, 18] . In our study, patients with pain were also significantly older than those without pain. Additionally, median EDSS, mean HDRS and HARS scores were significantly different between our patients with or without pain.
Depression is a common and disabling symptom in MS, with a point prevalence ranging from 27 to 54% [19, 20] . However, studies related to the prevalence of comorbidity of pain and depression are rather rare. Recently, Alschuler et al. emphasized that although, according to research from non-MS populations, pain and depression often co-occur and mutually impact each other, it is not clear whether the same phenomena are present for persons with MS [21] . The same authors reported that of persons experiencing any pain, 11-34% met depression criteria, and of persons meeting depression criteria, 86-100% reporting experiencing any pain [21] . Thus, they concluded, to our best knowledge in the first study reporting on the prevalence of this comorbidity, that this prevalence is 6-19%. Our results are in accordance with these previously published findings. We found the prevalence of the comorbidity of pain and depression in 29.1% of participants. Additionally, out of 288 persons experiencing any pain at the time of evaluation in our study, more than 65% met depression criteria. Regarding the difference in the comorbidity of pain and depression, in above mentioned studies, it should be mentioned that it has been previously published that comorbid pain and depression is suggested to exist in 27% of persons with neurologic conditions [22] . The significant correlations between presence of pain at the time of evaluation and both HDRS (P 5 0.001) and HARS (P 5 0.001) were registered. It should be emphasized that in three previously published cross-sectional studies with smaller cohorts of MS patients, association between pain and depression has been analyzed. Similar to our results, GrauLopez et al. found that pain was more frequent in MS patients with depression [23] . Conversely, pain was not found to be associated with depression in two remaining studies [24, 25] . Finally, in our multivariate linear regression analysis, only HARS (P < 0.001) was the independent predictor of pain in MS patients. These findings are clinically relevant and warrant further study, especially related to the treatment.
Appropriate approaches to treatment of pain in MS are not well defined yet. To optimize MS-related pain treatment, it is necessary to determine the origin of pain categories. Data related to treatment of pain in MS is very limited. In our study, about half of the patients were taking pain medication. Majority has taken nonsteroid antiinflammatory drugs, while trycyclic antidepressants, antiepileptic medications, and spasmolytics were used rarely.
Several limitations of this study require to be mentioned. This study was cross-sectional; longitudinal study which could have followed the evolution of pain during disease would have been preferable. Additionally, it should be mentioned that possible presence of information bias could have meaningful implication in interpretation of our findings. Namely, the information regarding pain during the entire course of the disease may be wrong and consequently, possible disagreement of correct answers can arise due to memory bias. This type of bias can also occur in circumstances when patients with longer duration of MS become adapted to pain and thus might not be recognized this issue as relevant. Furthermore, investigators were not blinded, and finally there was no control group of patients without MS. Finally, HDRS and HARS were used to identify depression and anxiety.
In conclusion, we confirmed in our survey high prevalence of pain, affecting approximately more than half of patients during the course of MS. Having in mind that pain in persons with MS is associated with disability and depression, it could potentially cause additional suffering and interfere significantly with daily activities. Until now, unfortunately the evidence for treating MS-related pain is very limited. Therefore, randomized controlled trials should be conducted to examine the efficacy and safety of various pharmacological treatments as well as nonpharmacologic therapies (psychotherapy, physical and occupational therapy).
